Inicijalna titracija doze
Licence Number PA1077/037/009
ReQuip Modutab
0 Read all of this leaflet carefully before you start taking this
It may improve your sleep by decreasing the urge to move your legs and decreasing uncomfortable/unpleasant feelings in the legs
The recommended dose
Dosage form: tablet, film coated Drug class: Dopaminergic antiparkinsonism agents Medically reviewed by Drugs
Therapeutic regimen: After the initial titration, weekly increments of 0
Talk to your doctor or pharmacist before taking Requip-Modutab: − if you are pregnant or think you may be pregnant − if you are breast feeding − if you are under 18 years old − if
Dose reduction/tapered discontinuation should be considered if such
How
Thus, is also used to treat a condition called Restless Legs Syndrome (RLS)
The recommended maximum total daily dose is 18 mg/day in patients receiving regular dialysis
Changes to the PIL after your medicine was packed may mean
«On-off»-Fluktuationen und die «end-of-dose»-Effekte, die mit der chronischen L-Dopa-Therapie auftreten, werden durch die Zusatztherapie mit Requip-Modutab vermindert
Dose reduction/tapered discontinuation should be considered if such symptoms develop
Requip/Requip-Modutab ne guérit pas la maladie, car il ne peut pas supprimer les causes du déficit en dopamine
Some people taking ReQuip-Modutab have fallen asleep during normal daytime activities such as working, talking, eating, or driving
Lek Requip Modutab može biti primenjen uz obrok ili nezavisno od njega (videti odeljak 5
5 to 1 mg three times daily (1
Active ingredient: Ropinirole 2mg, 4mg, 8mg
The recommended initial dose of REQUIP XL for patients with end-stage renal disease on hemodialysis is 2 mg once daily
Active Ingredient (s): Ropinirole Hydrochloride
It is the hydrochloride salt of 4-[2-(dipropylamino) ethyl]-1,3-dihydro-2H-indol-2-one monohydrochloride and has an empirical formula of C 16 H 24 N 2 O-HCl